Results 1 to 10 of about 62,558,702 (211)

Design and Optimization of Lornoxicam Dispersible Tablets Using Quality by Design (QbD) Approach [PDF]

Pharmaceuticals, 2022
The present study aims to design and optimize the lornoxicam dispersible tablet (LXDT) formulation using the Quality by design (QbD) approach. A randomized Box–Behnken experimental design was used to characterize the effect of the critical factors, such ...
Nawaf Almotairi, Gamal M. Mahrous, Saleh Al-suwayeh, Mohsin Kazi   +3 more
doaj   +5 more sources

Quality by Design (QbD) and Design of Experiments (DOE) as a Strategy for Tuning Lipid Nanoparticle Formulations for RNA Delivery [PDF]

Biomedicines, 2023
The successful development of nonviral delivery systems for nucleic acids has been reported extensively over the past years. Increasingly employed to improve the delivery efficiency and therapeutic efficacy of RNA are lipid nanoparticles (LNPs).
Lidia Gurba-Bryśkiewicz, Wioleta Maruszak, Damian A. Smuga, Krzysztof Dubiel, Maciej Wieczorek   +4 more
doaj   +4 more sources

Olaparib Process Development Employing Quality by Design (QbD) Principles [PDF]

ACS Omega
This study focuses on multivariate experimental design and statistical analysis to optimize the process of Olaparib 1. Quality by design (QbD) methodology was adopted for optimization of the Olaparib process consisting of three reaction steps: (1) amidation, (2) deprotection, and (3) acylation.
Amarendhar Manda, Shravan Kumar Komati, Sekhar Munaswamy Nariyam, Sasikala Cheemalapati Venkata Annapurna, Gopal Chandru Senadi, Arthanareeswari Maruthapillai, Rakeshwar Bandichhor   +6 more
doaj   +4 more sources

Quality by Design (QbD)-Driven Development and Optimization of Tacrolimus-Loaded Microemulsion for the Treatment of Skin Inflammation [PDF]

Pharmaceutics
Background: Skin inflammation represents a hallmark of many skin conditions, from psoriasis to eczema. Here, we present a novel microemulsion formulation for delivering a low dose of potent immunosuppressant, tacrolimus, to the skin for local ...
Sanjida Ahmed Srishti, Paromita Paul Pinky, Ryan Taylor, Jacob Guess, Natasha Karlik, Jelena M. Janjic   +5 more
doaj   +2 more sources

Quality by Design (QbD)-Based Numerical and Graphical Optimization Technique for the Development of Osmotic Pump Controlled-Release Metoclopramide HCl Tablets [PDF]

Drug Design, Development and Therapy, 2020
Sadaf Farooqi,1 Rabia Ismail Yousuf,1 Muhammad Harris Shoaib,1 Kamran Ahmed,1 Sabah Ansar,2 Tazeen Husain1 1Department of Pharmaceutics, Faculty of Pharmacy and Pharmaceutical Sciences, University of Karachi, Karachi 75270, Pakistan; 2Department of ...
Farooqi S, Yousuf RI, Shoaib MH, Ahmed K, Ansar S, Husain T   +5 more
doaj   +2 more sources

146 Applying and evaluating an enhanced “Quality by Design” program across the translational science spectrum [PDF]

Journal of Clinical and Translational Science
Objectives/Goals: To implement and evaluate the Quality by Design (QbD) framework integrating team science and project management to increase quality and efficiency in clinical and translational studies. Goals include achieving 80% on-time completion and
Cathelin Huang, Allison Orechwa, Thomas Buchanan, Kaelyn Moses, Saira Shah, Nicole Maccalla   +5 more
doaj   +2 more sources

Implementation of Quality by Design (QbD) Principles in Regulatory Dossiers of Medicinal Products in the European Union (EU) Between 2014 and 2019. [PDF]

Ther Innov Regul Sci, 2021
Ter Horst JP, Turimella SL, Metsers F, Zwiers A.   +3 more
europepmc   +2 more sources

Evaluations of Quality by Design (QbD) Elements Impact for Developing Niosomes as a Promising Topical Drug Delivery Platform. [PDF]

Pharmaceutics, 2020
Shah P, Goodyear B, Haq A, Puri V, Michniak-Kohn B.   +4 more
europepmc   +2 more sources

Double Optimization of Rivastigmine-Loaded Nanostructured Lipid Carriers (NLC) for Nose-to-Brain Delivery Using the Quality by Design (QbD) Approach: Formulation Variables and Instrumental Parameters. [PDF]

Pharmaceutics, 2020
Cunha S, Costa CP, Loureiro JA, Alves J, Peixoto AF, Forbes B, Sousa Lobo JM, Silva AC.   +7 more
europepmc   +2 more sources

Formulation Approaches for Improving the Dissolution Behavior and Bioavailability of Tolvaptan Using SMEDDS

Pharmaceutics, 2022
Tolvaptan, a selective vasopressin receptor antagonist, is a Class IV agent of Biopharmaceutical Classification System (BCS). To improve bioavailability after oral administration, the new tolvaptan-loaded self-microemulsifying drug delivery system ...
Jong-Hwa Lee, Gye-Won Lee
doaj   +1 more source